Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity

Article English OPEN
Barrett, Rachel M.A. ; Osborne, Toby P. ; Wheatley, Sally P. (2009)
  • Publisher: LANDES BIOSCIENCE, 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
  • Subject: QR
    mesheuropmc: neoplasms

Survivin is an essential chromosomal passenger protein required for mitotic progression. It is also an inhibitor of apoptosis and can prevent caspase-mediated cell death. In addition, survivin levels are elevated in cancer cells where its presence correlates with increased resistance to chemo- and radio-therapy, which makes it an attractive target for novel anti-cancer strategies. Interestingly, survivin is phosphorylated by the mitotic kinase, cdk1, and a non-phosphorylatable form, survivin(T34A), cannot inhibit apoptosis. Here we rigorously test the ability of survivin(T34A) and its corresponding phosphomimetic, survivin(T34E), to promote cell viability through survivin's dual roles. The effects of these mutations are diametrically opposed: survivin(T34A) accelerates cell proliferation and promotes apoptosis, whereas survivin(T34E) retards growth and promotes survival. Thus the phosphorylation status of survivin at T34 is pivotal to a cell's decision to live or die.
  • References (21)
    21 references, page 1 of 3

    1. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277:3247-57.

    2. Colnaghi R, Connell CM, Barrett RMA, Wheatley SP. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006; 281:33450-6.

    3. Connell CM, Colnaghi R, Wheatley SP. Nuclear survivin has reduced stability and is not cytoprotective. J Biol Chem 2008; 238:3289-96.

    4. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005; 65:4881-7.

    5. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8:61-70.

    6. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998; 273:11177-82.

    7. Shin S, Sung B-J, Cho Y-S, Kim H-J, Ha MC, Hwang J-I, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001; 40:1117-23.

    8. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP. Structure of the human antiapoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000; 7:602-8.

    9. Jahnke U, Higginbottom K, Newland AC, Cotter FE, Allen PD. Cell death in leukemia: Passenger protein regulation by topoisomerase inhibitors. Biochem Biophys Res Comm 2007; 361:928-33.

    10. O'Connor DS, Grossman D, Plescia J, Li FZ, Zhang H, Villa A, et al. Regulation of apoptosis at cell division by p34(cdc2) phosphorylation of survivin. Proc Natl Acad Sci USA 2000; 97:13103-7.

  • Metrics
    No metrics available
Share - Bookmark